Share on StockTwits

Incyte (NASDAQ:INCY) VP Laurent Chardonnet sold 34,000 shares of Incyte stock on the open market in a transaction dated Friday, May 2nd. The shares were sold at an average price of $51.55, for a total value of $1,752,700.00. Following the completion of the sale, the vice president now directly owns 3,811 shares of the company’s stock, valued at approximately $196,457. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Incyte (NASDAQ:INCY) traded down 0.19% during mid-day trading on Tuesday, hitting $53.38. The stock had a trading volume of 1,923,440 shares. Incyte has a 52 week low of $18.23 and a 52 week high of $70.86. The stock’s 50-day moving average is $51.0 and its 200-day moving average is $53.34. The company’s market cap is $8.836 billion.

Incyte (NASDAQ:INCY) last released its earnings data on Thursday, May 1st. The company reported ($0.21) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.04. The company had revenue of $89.80 million for the quarter, compared to the consensus estimate of $97.70 million. During the same quarter last year, the company posted ($0.12) earnings per share. Incyte’s revenue was up 26.3% compared to the same quarter last year. Analysts expect that Incyte will post $-0.57 EPS for the current fiscal year.

INCY has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Incyte in a research note on Monday. They now have a $54.00 price target on the stock. Separately, analysts at Nomura cut their price target on shares of Incyte from $93.00 to $90.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of Incyte in a research note on Tuesday, April 29th. They set an “outperform” rating and a $76.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating to the company. Incyte has an average rating of “Buy” and a consensus price target of $67.60.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.